SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01255059

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

GWAS Research of Lung Cancer by Department of Epidemiology and Biostatistics in Tianjin Medical University Cancer Institute and Hospital

To study the association of Genetic Polymorphisms with Lung Cancer Risk in Tianjin Population.

NCT01255059 Non-small Cell Lung Cancer Primary Carcinoma
MeSH:Lung Neoplasms
HPO:Neoplasm of the lung


Primary Outcomes

Description: A GWAS reported a novel association between the TP63 locus and risk of lung adenocarcinoma; however, this association did not achieve genome-wide significance among never-smoking males or females. We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China. Genetic variation in rs10937405 was associated with lung adenocarcinoma. Our findings provide strong evidence that genetic variation in TP63 is associated with risk of lung adenocarcinoma among non-smoking females.

Measure: Genetic variant in TP63 on locus 3q28 is associated with risk of lung adenocarcinoma among never-smoking females in Asia

Time: 2011-12

Time Perspective: Retrospective

Case Control


There are 2 SNPs

SNPs


1 rs10937405

We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China.

Genetic variation in rs10937405 was associated with lung adenocarcinoma.


2 rs4488809

We genotyped the TP63 SNPs reported by the previous GWAS (rs10937405 and rs4488809) in 500 never-smoking female lung cancer cases and 500 never-smoking female controls from China.



HPO Nodes


HPO: